|Awarded On||August 18, 2021|
|Title||Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Institution/Organization||Dialectic Therapeutics, Inc.|
|Principal Investigator/Program Director||Joshua Sills|
|Cancer Sites||All Sites|
Dialectic Therapeutics (DT) is a biotech start up dedicated to the development of impactful and unique anti-cancer drugs to effectively treat cancers with few to no other options. Founded by three respected cancer scientists and two successful biotech investors, DT is located in Dallas and has research facilities/partners at UT Health in San Antonio (UTHSA) and the University of Florida. DT’s lead candidate, DT2216, is a unique programmed protein degradation compound that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on their own, or become more susceptible to chemotherapy. Cancer cells are less likely to develop resistance to DT2216 because of i...